assess if long-term prediction of severe hypoglycemia is possible in type 1 diabetes.
Methods

Patients and Design
From 1999 to 2001, 269 outpatients with type 1 diabetes followed at Nordsjaellands Hospital Hillerød were consecutively enrolled in a cross-sectional study. In 2012, it was possible to reexamine 98 of these patients (during follow-up, 39 patients had died, 60 patients had ended their control at our outpatient clinic and 71 patients declined to participate in the follow-up study in 2012). At entry, included patients were adults (>18 years) with type 1 diabetes for more than 2 years. Pregnant women, patients with end-stage renal disease or with concomitant malignant disease were excluded from participation.
In this study, we defined short-term prediction of hypoglycemia as prediction of hypoglycemia over a period of 1 year or less and long-term prediction as the ability to predict the risk of severe hypoglycemia over a period of more than 1 year.
The Regional Committee on Biomedical Research Ethics approved the study.
Questionnaires
At baseline and at follow-up in 2012, the patients filled in a questionnaire about number of severe hypoglycemic episodes in the preceding year and self-estimated state of hypoglycemia awareness. The questionnaire has been described in previous studies. 5 Information about history of diabetes, treatment and late complications were extracted from the patients' medical records at baseline and follow-up.
Severe hypoglycemia was defined as an episode requiring assistance of another person actively to correct the plasma glucose to normal. 12 The primary end-point was the rate of severe hypoglycemic episodes in the preceding year. Oneyear recall of rate of severe hypoglycemia is a validated measure as shown previously in this cohort. 13 State of awareness was assessed by the validated Hillerød method based on the question: "Do you recognize symptoms, when you have a hypo?" According to the answer, patients are classified as having normal or impaired awareness or hypoglycemia unawareness. 13, 14 Thus, this method divides hypoglycemia awareness into 3 groups.
Laboratory Analyses
HbA1c and C-peptide were measured at baseline and at follow-up. If C-peptide levels were undetectable (<10 pmol/l), the patient was classified as C-peptide negative.
Statistical Analyses
Standard descriptive statistics were used to characterize patients at baseline and follow-up. Comparisons between variables were made by parametric (chi-square test, pairedsamples t-test) and nonparametric (Wilcoxon signed rank test) methods as appropriate. The influence of well-known risk factors on number of severe hypoglycemic events were assessed by a log-linear negative binomial model, which takes into account the skewed distribution of events of severe hypoglycemia. The risk factors included in the analysis were state of hypoglycemia awareness, duration of diabetes, HbA1c and C-peptide status. Calculations were done by using SPSS software package (Version 22.0). Level of statistical significance was chosen as P value < .05 (2-sided).
Results
Baseline characteristics of the patients are shown in Table 1 . At baseline, there were no significant differences between the 98 participants and 171 nonparticipants according to age, diabetes duration, HbA1c, or awareness status but peripheral neuropathy and macrovascular complications were more frequent in nonparticipants. Of the participants, 57% were male, and at baseline the mean age was 44 years and the mean duration of diabetes was 20 years. In 2012, 98 patients participated in the follow-up with a median follow-up of 12 years.
From baseline to follow-up, the percentage of C-peptidenegative patients increased from 42% at baseline to 91% at follow-up (P < .001) while the average HbA1c level decreased from 72 mmol/mol to 63 mmol/mol (P < .001) ( Table 1 ). Only few patients were treated with insulin analogs or insulin pumps at baseline while at follow-up 58% and 21% of the patients used these treatment modalities, respectively (P < .001). The daily dose of insulin did not change in the follow-up period.
The yearly prevalence of severe hypoglycemia decreased from 38% at baseline to 22% at follow-up. The incidence of severe hypoglycemia decreased from 1.1 episodes per patientyear at baseline to 0.4 (P < .001) episodes per patient-year at follow-up. Although the prevalence of impaired awareness and unawareness of hypoglycemia was unaltered during follow-up, a significant portion of the patients (39%) changed state of awareness from baseline to follow-up (P < .001), including 17% with improved and 21% with decreased hypoglycemia awareness after 12 years of follow-up (Table 2) .
Severe Hypoglycemia and State of Awareness
At baseline, patients classified as having impaired awareness and unawareness of hypoglycemia had a 3.6-fold (95% CI 1.7-7.6; P = .001) and 10.9-fold (95% CI 4.4-27.3; P < .0001) increased relative rate of severe hypoglycemia, respectively, as compared to patients with normal awareness of hypoglycemia (Table 3A) . State of awareness at baseline was not associated with rate of severe hypoglycemia at follow-up with relative rates of 0.8 (95% CI 0.4-1.5) and 1.1 (95% CI 0.4-3.0) in patients with impaired awareness and unawareness, respectively, as compared to patients with normal hypoglycemia awareness. However, at follow-up, 1 single patient classified as having normal awareness accounted for a third of the total number of severe hypoglycemic events. If excluding this patient from the analyses, state of awareness at baseline corresponded to a 1.4-fold (95% CI 0.5-3.7) increased rate of severe hypoglycemia for impaired awareness and a 3.1-fold (95% CI 0.9-10.5; P = .07) increased relative rate for unaware patients as compared to patients with normal awareness of hypoglycemia. Patients classified with impaired awareness and unawareness at follow-up had a relative rate of 3.3 (95% CI 0.9-12.2) and 10.3 (95% CI 2.3-44.3; P = .002), respectively, as compared to patients with normal awareness of hypoglycemia.
Severe Hypoglycemia and Other Risk Factors
As shown in Table 3B , C-peptide-negative patients had a 2.6-fold (95% CI 1.5-4.6; P = .001) increased rate of severe hypoglycemia at baseline as compared to patients with a detectable level of C-peptide. The level of C-peptide measured at baseline was not associated with the rate of severe hypoglycemia at follow-up (relative rate 1.0; 95% CI 0.4-2.4). Neither at baseline nor at follow-up was HbA1c level, long duration of diabetes, or gender associated with the rate of severe hypoglycemia.
Discussion
In this cohort of patients with type 1 diabetes we were unable to predict severe hypoglycemia from well-known risk factors assessed 12 years earlier despite the fact that the expected associations between the risk factors and severe hypoglycemia were observed with expected and comparable strength both at baseline and at the follow-up. At baseline, there was a correlation between state of awareness and C-peptide status and rate of severe hypoglycemia. This is in line with earlier studies also reporting these factors to be short-term risk factors for severe hypoglycemia. [4] [5] [6] Especially, state of awareness was a strong predictor for the short-term risk of severe hypoglycemia. Our study confirms that the increased short-term risk is replicable over time as an approximately 10-fold higher risk of severe hypoglycemia for patients with hypoglycemia unawareness was found both at baseline and at follow-up. At follow-up, there was a trend toward a 3.1-fold increased rate of severe hypoglycemia in those with unawareness at baseline. This suggests that although unawareness predicts severe hypoglycemia over a period of at least 12 years, the effect is declining with time. The fact, that only patients with the most severely impaired awareness of hypoglycemia (ie, unawareness assessed by the Hillerød-method, normally comprising 10-15% of the type 1 diabetes population 14 ) at baseline tended to have a persisting increased risk of severe hypoglycemia at follow-up may be explained by a significant number of patients altering state of awareness from baseline to follow-up. Thus state of awareness is not stable over time but can both be regained or deteriorate, for example due to avoidance of hypoglycemia or tight glycemic control, respectively. There was no association between HbA1c or C-peptide levels determined at baseline and rate of severe hypoglycemia at follow-up, that is, HbA1c and C-peptide levels did not predict risk of severe hypoglycemia over a longer period than 1 year in this cohort. This may likewise be explained by the significant alterations in both HbA1c and C-peptide status during the follow-up time, for example, 91% of the patients were C-peptide-negative at follow-up, which may have resulted in loss of power. During the 12 years of follow-up in our study, we observed a significant decrease in the incidence of severe hypoglycemia from 1.1 episodes per patient-year to 0.4 episodes per patient-year, corresponding to an approximately 50% decrease in the prevalence of severe hypoglycemic events. The incidence of 0.4 episodes of severe hypoglycemia per patient-year is much lower than in previous studies reporting an incidence of severe hypoglycemia of 1-1.5 episodes per patient-year. 2, 13, 15, 16 Despite the decreasing rate of severe hypoglycemia, we showed a simultaneous decrease in both HbA1c and detectable C-peptide levels in our cohort. The prevalence of impaired awareness and unawareness of hypoglycemia did not differ from baseline to follow-up and therefore the lower rate of severe hypoglycemia is not due to a regained awareness of hypoglycemia. Moreover, it is not due to a selection bias, as the nonparticipants in the baseline cohort did not differ from the participants according to baseline C-peptide status, duration of diabetes or HbA1c. Only few studies explore the rate of severe hypoglycemia and risk factors over a longer period than 1 year. 8, 9 These long-term studies find unaltered 9 or increased 8 rates of severe hypoglycemia in contrast to the declining rate in our study. We speculate that the reduced rate in our cohort is explained by the constant focus on problematic hypoglycemia in our diabetes outpatient clinic during the study period. Moreover, improvements in the diabetes management implemented after ending followup in the other long-term studies, 8, 9 for example, insulin analogs and insulin pumps, may be of influence. Thus, during the 12 years of follow-up in our study, use of insulin analogs has become much more frequent in the management of type 1 diabetes and insulin analogs are shown to reduce the risk of hypoglycemia. [17] [18] [19] The increase in the use of analogs in our study from 5% at baseline to 58% at the end of follow-up in 2012 may explain some of the decline in rate of severe hypoglycemia in our study as compared to the earlier long-term studies. However, the implementation of insulin analogs and pumps were not limited to patients prone to severe hypoglycemia or with reduced awareness of hypoglycemia at baseline, that is, the intervention during follow-up were balanced. This may emphasize the importance of a constant focus on problematic hypoglycemic episodes and their prevention in outpatient clinics to reduce the rate of severe hypoglycemia. Finally, in 2012, the driver's license legislation has been tightened up in Denmark and in the European Union, which may have influenced the patients' willingness to report severe hypoglycemic events at follow-up. 20, 21 
Conclusion
Long-term prediction of severe hypoglycemia in type 1 diabetes is difficult. In this study, we demonstrate that prediction of the long-term risk of severe hypoglycemia is not possible based on well-known risk factors for severe hypoglycemia. However, the strongest risk predictor of severe hypoglycemia, that is, self-estimated unawareness of hypoglycemia, tended to predict an increased long-term rate of severe hypoglycemia, even though the effect weakened over time. Therefore, it is important repeatedly to assess risk factors of severe hypoglycemia in type 1 diabetes, for example, state of hypoglycemia awareness and C-peptide status. By repeating assessment of the well-known risk factors, it may be possible to estimate the present risk of severe hypoglycemia in patients with type 1 diabetes.
Abbreviations CI, confidence interval; RR, relative rate; SH, severe hypoglycemia.
